Agenda
10.00 - 10.20
Welcome & Introduction
Claudia Ivascu, Head of Task Force Liquid Biopsy & Saskia Biskup, CeGaT GmbH, Tübingen
10.20 - 11.10
Opportunities and Chances: Where is the added value in the use of liquid biopsy and which hurdles are still to be overcome?
Liquid Biopsy from a clinical perspective
Nikolas von Bubnoff, Universitätsklinikum Schleswig-Holstein
Companion diagnostics in the context of IVDR
Philipp Schatz, Bayer AG
11.30 - 12.00
Round Tables
Join and discuss one of the following topics:
- Liquid profiling outside cancer - most promising indications?
- Liquid biopsy in screening and early detection - ready for prime time?
- AI on Liquid Biopsy profiling data and clinical outcomes
- Regulatory and Reimbursement Topics
13.00 - 15.40
Development and Collaboration: What's new and how does it reach the patients' bedside?
BloodPAC Consortium: Defining Standards to Accelerate Development, Approval & Accessibility
Lauren Leiman, Executive Director BloodPAC
Developing an Advanced Diagnostics Ecosystem in Europe
Benjamin Gannon, EUCOPE Advanced Dx Working Group
Company Presentations
- CeGaT GmbH - Saskia Biskup
- Foundation Medicine - David Liesenfeld, Medical Manager Roche Pharma AG
- GILUPI GmbH - Christian Jurinke
- Guardant Health - Benjamin Gannon
- Hummingbird Diagnostics GmbH - Bruno Steinkraus
- HS Analysis GmbH - Valentin Haas
- Qiagen GmbH - Martin Schlumpberger
- Telexos GmbH - Erhard Fernholz
Possibilities and limitations of autonomous AI systems for diagnosis and research of CTCs/cfDNA
Sergey Biniaminov, HS Analysis GmbH
